Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Quest Diagnostics (DGX) or The Pennant Group, Inc. (PNTG) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive ...

Quest Diagnostics Incorporated (NYSE:DGX) Q3 2024 Earnings Conference Call October 22, 2023 8:30 AM ET Company Participants Jim Davis - President, Chief Executive Officer Sam Samad - Executive Vice President, Chief Financial Officer Shawn Bevec - Vice President, Investor Relations Conference Call Participants Ann Hynes - Mizuho Securities Michael Cherny - Leerink Partners Patrick Donnelly - Citi Pito Chickering - Deutsche Bank Meghan Holtz - Jefferies David Westenberg - Piper Sandler Jack Meehan - Nephron ...

Quest Diagnostics Inc DGX posted third-quarter adjusted earnings per share of $2.30, beating the consensus of $2.26.Sales increased 8.5% year-over-year to $2.49 billion, beating the consensus of $2.42 billion.Quest Diagnostics saw total revenue growth of 8.5%, including 4.2% organic growth, said Quest Diagnostics CEO Jim Davis. “Our performance was driven by new customer wins and expanded business with physicians and hospitals, as well as recent acquisitions, including LifeLabs,” he added. “We are now on tr ...

Quest Diagnostics Incorporated’s (DGX) third-quarter 2024 adjusted earnings per share (EPS) of $2.30 beat the Zacks Consensus Estimate by 1.8%. The metric also exceeded the year-ago adjusted figure by 3.6%.Certain one-time expenses, like the ones related to amortization expenses, certain restructuring and integration charges, other expenses and excess tax benefits associated with stock-based compensations, were excluded from the quarter’s adjusted figures.GAAP earnings came in at $1.99 per share, up 1.5% fr ...

Quest Diagnostics (DGX) came out with quarterly earnings of $2.30 per share, beating the Zacks Consensus Estimate of $2.26 per share. This compares to earnings of $2.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.77%. A quarter ago, it was expected that this medical laboratory operator would post earnings of $2.31 per share when it actually produced earnings of $2.35, delivering a surprise of 1.73%.Over the last four qua ...

Revenue and Earnings Performance - Third quarter revenues of $2.49 billion, up 8.5% from 2023[1] - Third quarter reported diluted EPS of $1.99, up 1.5% from 2023; adjusted diluted EPS of $2.30, up 3.6% from 2023[1] - Full year 2024 revenues expected to be between $9.80 billion and $9.85 billion; reported diluted EPS expected to be between $7.60 and $7.70; adjusted diluted EPS expected to be between $8.85 and $8.95[1] - Diagnostic Information Services revenues of $2.427 billion, up 9.0% from 2023[2] - Revenue per requisition increased by 3.3% and requisition volume increased by 5.5% in the third quarter[2] - Adjusted operating income increased by 1.3% to $385 million in the third quarter[2] - Adjusted net income attributable to Quest Diagnostics increased by 3.1% to $262 million in the third quarter[2] - Net income attributable to Quest Diagnostics was $649 million for the nine months ended September 2024, slightly down from $662 million in 2023[14] - Diluted earnings per share (EPS) for the nine months ended September 2024 was $5.74, compared to $5.79 in 2023[14] - Adjusted operating income for the nine months ended September 2024 was $1,132 million, representing 15.6% of net revenues[17] - Adjusted diluted EPS for the nine months ended September 2024 was $6.70, up from $5.79 in 2023[17] - Operating income for the nine months ended September 30, 2023, was $995 million, representing 14.3% of net revenues[19] - Adjusted operating income for the same period was $1,119 million, or 16.1% of net revenues[19] Cash Flow and Financial Position - Cash provided by operations increased by 72.5% to $356 million in the third quarter[2] - Net cash provided by operating activities was $870 million for the nine months ended September 2024, compared to $745 million in the same period in 2023[13] - Cash and cash equivalents increased to $764 million in September 2024 from $686 million in December 2023[11] - Long-term debt rose to $5,648 million in September 2024 from $4,410 million in December 2023[11] - Business acquisitions, net of cash acquired, totaled $1,781 million for the nine months ended September 2024[13] - Capital expenditures were $302 million for the nine months ended September 2024, down from $336 million in 2023[13] Acquisitions and Growth - The company has completed eight acquisitions by year-end, contributing to revenue growth and profitability[2] - Total assets increased to $16,095 million in September 2024 from $14,022 million in December 2023, reflecting growth in goodwill and intangible assets[11] - Pre-tax losses of $13 million are expected in 2024 due to the increase in fair value of contingent consideration from previous acquisitions[24] - Pre-tax losses of $11 million are anticipated in 2024 from changes in the carrying value of strategic investments[24] - A non-recurring pre-tax gain of $8 million is expected in 2024 from a foreign exchange forward contract related to an acquisition[25] Restructuring and Integration - Restructuring and integration charges for the nine months ended September 30, 2023, totaled $32 million, with a pre-tax impact of $45 million[21] - Estimated pre-tax restructuring and integration charges for 2024 are $50 million, primarily related to workforce reductions[24] - Estimated pre-tax amortization expenses for 2024 are $129 million[24] - Amortization expense for the nine months ended September 30, 2023, was $81 million[19] External Factors Impact - The company expects Hurricane Milton to negatively impact net revenues by approximately $15 million and EPS by approximately 8 cents in the fourth quarter[3]

Wall Street expects a year-over-year increase in earnings on higher revenues when Quest Diagnostics (DGX) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on October 22, 2024, might help the stock move higher if these key numbers are bette ...

First-of-its-kind service empowers discreet and more convenient access to testing and treatment for vaginitis and similar genital tract infections such as chlamydia, gonorrhea, trichomoniasis and Mycoplasma genitalium Self-collection option available at no extra charge at any of Quest's 2,000 patient service centers with a physician's order or through Quest's consumer-initiated test platform at questhealth.com SECAUCUS, N.J., Oct. 15, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnosti ...

The medical laboratory testing industry is growing at a 1-3% compound annual growth rate and is dominated by two publicly traded companies. Quest Diagnostics (NYSE: DGX ) is the stronger of the two companies and is actively I am an individual investor with over two decades of investing experience. I am passionate about finding great value buys and pursuing dividend growth investing, from domestic to international companies. I invest in businesses, not stocks!I cover all aspects of value investing, dividend ...

Quest Diagnostics (DGX) is set to release its third-quarter 2024 results on Oct. 22, before the opening bell. The medical diagnostic testing provider posted adjusted earnings per share (EPS) of $2.35 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 1.73%. The company topped earnings estimates in each of the trailing four quarters, the average surprise being 3.31%. Find the latest EPS estimates and surprises on Zacks Earnings Calendar. DGX's Q3 Estimates For the third quarter of ...